Literature DB >> 18940913

Signaling through urokinase and urokinase receptor in lung cancer cells requires interactions with beta1 integrins.

Chi-Hui Tang1, Marla L Hill, Alexis N Brumwell, Harold A Chapman, Ying Wei.   

Abstract

The urokinase receptor (uPAR) is upregulated upon tumor cell invasion and correlates with poor lung cancer survival. Although a cis-interaction with integrins has been ascribed to uPAR, whether this interaction alone is critical to urokinase (uPA)- and uPAR-dependent signaling and tumor promotion is unclear. Here we report the functional consequences of point mutations of uPAR (H249A-D262A) that eliminate beta1 integrin interactions but maintain uPA binding, vitronectin attachment and association with alphaV integrins, caveolin and epidermal growth factor receptor. Disruption of uPAR interactions with beta1 integrins recapitulated previously reported findings with beta1-integrin-derived peptides that attenuated matrix-dependent ERK activation, MMP expression and in vitro migration by human lung adenocarcinoma cell lines. The uPAR mutant cells acquired enhanced capacity to adhere to vitronectin via uPAR-alphaVbeta5-integrin, rather than through the uPAR-alpha3beta1-integrin complex and they were unable to initiate uPA signaling to activate ERK, Akt or Stat1. In an orthotopic lung cancer model, uPAR mutant cells exhibited reduced tumor size compared with cells expressing wild-type uPAR. Taken together, the results indicate that uPAR-beta1-integrin interactions are essential to signals induced by integrin matrix ligands or uPA that support lung cancer cell invasion in vitro and progression in vivo.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18940913      PMCID: PMC3903460          DOI: 10.1242/jcs.029769

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  53 in total

1.  Altered expression and function of beta1 integrins in a highly metastatic human lung adenocarcinoma cell line.

Authors:  K Takenaka; M Shibuya; Y Takeda; S Hibino; A Gemma; Y Ono; S Kudoh
Journal:  Int J Oncol       Date:  2000-12       Impact factor: 5.650

2.  Significance of coexpression of urokinase-type plasminogen activator, and matrix metalloproteinase 3 (stromelysin) and 9 (gelatinase B) in colorectal carcinoma.

Authors:  K Inuzuka; Y Ogata; H Nagase; K Shirouzu
Journal:  J Surg Res       Date:  2000-10       Impact factor: 2.192

3.  Activation of urokinase receptor by a novel interaction between the connecting peptide region of urokinase and alpha v beta 5 integrin.

Authors:  Paola Franco; Immacolata Vocca; Maria V Carriero; Daniela Alfano; Letizia Cito; Immacolata Longanesi-Cattani; Paolo Grieco; Liliana Ossowski; Maria P Stoppelli
Journal:  J Cell Sci       Date:  2006-08-01       Impact factor: 5.285

4.  Urokinase receptors are required for alpha 5 beta 1 integrin-mediated signaling in tumor cells.

Authors:  Ying Wei; Chi-Hui Tang; Young Kim; Liliane Robillard; Feng Zhang; Matthias C Kugler; Harold A Chapman
Journal:  J Biol Chem       Date:  2006-12-04       Impact factor: 5.157

5.  Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: relation to prognosis and angiogenesis.

Authors:  Birgitte Vrou Offersen; Per Pfeiffer; Peter Andreasen; Jens Overgaard
Journal:  Lung Cancer       Date:  2007-01-17       Impact factor: 5.705

6.  Kininostatin associates with membrane rafts and inhibits alpha(v)beta3 integrin activation in human umbilical vein endothelial cells.

Authors:  Yi Wu; Victor Rizzo; Yuchuan Liu; Irma M Sainz; Noah G Schmuckler; Robert W Colman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-06-21       Impact factor: 8.311

7.  Urokinase receptor interacts with alpha(v)beta5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer.

Authors:  M V Carriero; S Del Vecchio; M Capozzoli; P Franco; L Fontana; A Zannetti; G Botti; G D'Aiuto; M Salvatore; M P Stoppelli
Journal:  Cancer Res       Date:  1999-10-15       Impact factor: 12.701

8.  Proteomic identification of lynchpin urokinase plasminogen activator receptor protein interactions associated with epithelial cancer malignancy.

Authors:  Rohit G Saldanha; Mark P Molloy; Khalil Bdeir; Douglas B Cines; Xiaomin Song; Pauliina M Uitto; Paul H Weinreb; Shelia M Violette; Mark S Baker
Journal:  J Proteome Res       Date:  2007-03       Impact factor: 4.466

9.  Cancer statistics, 2007.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Taylor Murray; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2007 Jan-Feb       Impact factor: 508.702

10.  Modification of kidney barrier function by the urokinase receptor.

Authors:  Changli Wei; Clemens C Möller; Mehmet M Altintas; Jing Li; Karin Schwarz; Serena Zacchigna; Liang Xie; Anna Henger; Holger Schmid; Maria P Rastaldi; Peter Cowan; Matthias Kretzler; Roberto Parrilla; Moïse Bendayan; Vineet Gupta; Boris Nikolic; Raghu Kalluri; Peter Carmeliet; Peter Mundel; Jochen Reiser
Journal:  Nat Med       Date:  2007-12-16       Impact factor: 53.440

View more
  31 in total

1.  An anti-urokinase plasminogen activator receptor antibody (ATN-658) blocks prostate cancer invasion, migration, growth, and experimental skeletal metastasis in vitro and in vivo.

Authors:  Shafaat A Rabbani; Bushra Ateeq; Ani Arakelian; Maria Luisa Valentino; David E Shaw; Lisa M Dauffenbach; Christopher A Kerfoot; Andrew P Mazar
Journal:  Neoplasia       Date:  2010-10       Impact factor: 5.715

2.  Design, synthesis, biochemical studies, cellular characterization, and structure-based computational studies of small molecules targeting the urokinase receptor.

Authors:  Fang Wang; W Eric Knabe; Liwei Li; Inha Jo; Timmy Mani; Hartmut Roehm; Kyungsoo Oh; Jing Li; May Khanna; Samy O Meroueh
Journal:  Bioorg Med Chem       Date:  2012-06-12       Impact factor: 3.641

3.  Antagonistic anti-urokinase plasminogen activator receptor (uPAR) antibodies significantly inhibit uPAR-mediated cellular signaling and migration.

Authors:  Sai Duriseti; David H Goetz; Daniel R Hostetter; Aaron M LeBeau; Ying Wei; Charles S Craik
Journal:  J Biol Chem       Date:  2010-05-25       Impact factor: 5.157

4.  Fibulin-5 binds urokinase-type plasminogen activator and mediates urokinase-stimulated β1-integrin-dependent cell migration.

Authors:  Alexander Kapustin; Victoria Stepanova; Natalia Aniol; Douglas B Cines; Alexei Poliakov; Serge Yarovoi; Tatiana Lebedeva; Robin Wait; Grigory Ryzhakov; Yelena Parfyonova; Yaroslav Gursky; Hiromi Yanagisawa; Mikhail Minashkin; Robert Beabealashvilli; Alexander Vorotnikov; Alex Bobik; Vsevolod Tkachuk
Journal:  Biochem J       Date:  2012-04-15       Impact factor: 3.857

5.  Effects of integrins on laminin chemotaxis by hepatocellular carcinoma cells.

Authors:  Bian-Hong Fu; Ze-Zhi Wu; Jian Qin
Journal:  Mol Biol Rep       Date:  2009-09-21       Impact factor: 2.316

6.  uPAR promotes tumor-like biologic behaviors of fibroblast-like synoviocytes through PI3K/Akt signaling pathway in patients with rheumatoid arthritis.

Authors:  Yan Liu; Yun Feng Pan; You-Qiu Xue; Lin-Kai Fang; Xing-Hua Guo; Xin Guo; Meng Liu; Bi-Yao Mo; Meng-Ru Yang; Fang Liu; Yun-Ting Wu; Nancy Olsen; Song Guo Zheng
Journal:  Cell Mol Immunol       Date:  2017-01-16       Impact factor: 11.530

7.  Role of integrins in regulating proteases to mediate extracellular matrix remodeling.

Authors:  Jiao Yue; Kun Zhang; Jianfeng Chen
Journal:  Cancer Microenviron       Date:  2012-03-22

8.  A novel peptide blocking cancer cell invasion by structure-based drug design.

Authors:  Yuki Yamada; Seiji Kanayama; Fuminori Ito; Noriyuki Kurita; Hiroshi Kobayashi
Journal:  Biomed Rep       Date:  2017-07-31

9.  Suppression of uPAR retards radiation-induced invasion and migration mediated by integrin β1/FAK signaling in medulloblastoma.

Authors:  Arun Kumar Nalla; Swapna Asuthkar; Praveen Bhoopathi; Meena Gujrati; Dzung H Dinh; Jasti S Rao
Journal:  PLoS One       Date:  2010-09-24       Impact factor: 3.240

10.  Domain 2 of uPAR regulates single-chain urokinase-mediated angiogenesis through β1-integrin and VEGFR2.

Authors:  Gretchen A Larusch; Alona Merkulova; Fakhri Mahdi; Zia Shariat-Madar; Robert G Sitrin; Douglas B Cines; Alvin H Schmaier
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-05-24       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.